Prelude Therapeutics stock narrows Q3 net loss to USD 12.5 million
Published on 11/19/2026 at 03:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly results and pipeline
- Phase 1 enrollment is underway for PRT13722 in HR-positive breast cancer.
- Prelude expects initial proof-of-concept data in the second half of 2027.
- The company expects its cash resources to fund operations into the second quarter of 2028.
Prelude Therapeutics reported a narrower third-quarter net loss on Monday, November 16, for the period ended September 30, 2026. The clinical-stage oncology company posted a net loss of USD 12.5 million, or USD 0.12 per share, compared with USD 19.7 million, or USD 0.26 per share, a year earlier, according to GlobeNewswire.
Loss narrows as spending falls
Revenue declined to USD 5.647 million from USD 6.500 million in the year-earlier quarter. Research and development expense fell to USD 14.8 million from USD 21.7 million, while general and administrative expense eased to USD 5.1 million from USD 5.2 million.
The company said lower spending on paused SMARCA2 trials and reduced employee-related costs contributed to the decline in research and development expense. Non-cash stock-based compensation included in research and development expense was USD 0.9 million, compared with USD 1.4 million a year earlier.
Clinical milestones move forward
Enrollment is underway in the Phase 1 study of PRT13722, an oral KAT6A degrader for patients with HR-positive, HER2-negative breast cancer. Prelude expects initial proof-of-concept data in the second half of 2027.
Prelude also continues to enroll patients in a Phase 1 study of PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis. In October, the company entered a clinical trial collaboration and supply agreement with Eli Lilly to evaluate PRT13722 in combination with abemaciclib and imlunestrant.
Cash runway extends into 2028
Cash, cash equivalents, restricted cash and marketable securities totaled USD 142.7 million at September 30. Prelude expects those resources to fund operations into the second quarter of 2028, supporting further clinical development and planned data readouts.
Precision oncology business
Prelude Therapeutics develops precision oncology medicines for areas of high unmet need. Its pipeline includes selective KAT6A degraders, mutant-selective JAK2V617F inhibitors and degrader antibody conjugates targeting mutant calreticulin. The company is based in Wilmington, Delaware, and focuses on research and clinical development rather than commercial products.
Prelude Therapeutics at a glance
- Company: Prelude Therapeutics Incorporated
- ISIN: US74065P1012
- Ticker: PRLD
- Home exchange: Nasdaq
- Third-quarter net loss: USD 12.5 million for the period ended September 30, 2026
- Cash, cash equivalents, restricted cash and marketable securities: USD 142.7 million at September 30, 2026
The US stock market environment remains the broader reference point for U.S.-listed biotechnology companies.
